There are currently 1140 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Recruiting
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/23/2024
Locations: Alkermes Investigator Site, Cincinnati, Ohio
Conditions: Schizophrenia, Bipolar I Disorder
SPEARHEAD-3 Pediatric Study
Recruiting
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-21 years of age with advanced cancers
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
04/23/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma, Osteosarcoma
Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults
Recruiting
The goal of this study is to evaluate the usefulness of hyperpolarized (HP) 129Xe (xenon) gas MRI for regional assessment of lung function in a normal population of children and adults and in adults and also in children with respiratory compromise due to a variety of diseases.
Gender:
All
Ages:
6 years and above
Trial Updated:
04/23/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Respiratory Disorders
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/22/2024
Locations: Clinical Site, Cincinnati, Ohio
Conditions: Bipolar Depression
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
J-Valve TF Early Feasibility Study
Recruiting
The main objective of this study is to assess the preliminary safety and effectiveness of the J-Valve TF System in patients with symptomatic severe native aortic regurgitation who are judged by a multi-disciplinary heart team to be eligible for the device and to be at high risk for open surgical aortic valve replacement.
Gender:
All
Ages:
All
Trial Updated:
04/19/2024
Locations: The Christ Hospital, Cincinnati, Ohio
Conditions: Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Recruiting
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy, will receive pembrolizumab therapy or pembrolizumab in combination with other investigational agents. The primary study hypothesis is that treatment with pembrolizumab will result in a clinically meaningful response.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Call for Information (Investigational Site 0072), Cincinnati, Ohio
Conditions: Bladder Cancer
Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea
Recruiting
This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and t... Read More
Gender:
All
Ages:
Between 10 years and 21 years
Trial Updated:
04/19/2024
Locations: Cincinnati Childrens Hospital, Cincinnati, Ohio
Conditions: Down Syndrome, Obstructive Sleep Apnea
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Recruiting
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio
Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Recruiting
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: POMC or PCSK1 (Sub-study 035a) LEPR (Sub-study 035b) SRC1 (Sub-study 035c) SH2B1 (Sub-study 035d) The objectives and endpoints are identical for these sub-studies.
Gender:
All
Ages:
Between 6 years and 65 years
Trial Updated:
04/19/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Obesity, Genetic Obesity
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
04/19/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio +1 locations
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Recruiting
The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Glioblastoma, Skin Toxicity, Recurrent Glioblastoma